Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bradford Katchen

Dermatology New York, NY Medical Doctor

NPI 1801815022 CMS profile 126647

568 Broadway, Suite 303, New York, NY 10012

Open in the dashboard

General payments

$4,178

204 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bradford Katchen of New York, NY is reported in the CMS Open Payments database as having received $4,178 across 204 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,127 49
2024 General $882 53
2023 General $957 41
2022 General $509 19
2021 General $286 12
2020 General $86 4
2019 General $330 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bradford Katchen
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Bradford Katchen were reported at $1,127. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Bradford Katchen Dermatology median Middle half National median
2019 $330 $454 $129–$1,240 $163
2020 $86 $235 $81–$756 $114
2021 $286 $377 $108–$1,108 $132
2022 $509 $514 $143–$1,391 $149
2023 $957 $607 $159–$1,674 $160
2024 $882 $751 $204–$1,903 $164
2025 $1,127 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $722 47 payments
  2. Mayne Pharma Inc. $590 38 payments
  3. Regeneron Healthcare Solutions, Inc. $454 17 payments
  4. Arcutis Biotherapeutics, Inc. $308 11 payments
  5. Almirall LLC $291 14 payments
  6. Genzyme Corporation $194 8 payments
  7. Janssen Biotech, Inc. $191 6 payments
  8. LEO Pharma Inc. $186 8 payments
  9. Pfizer Inc. $175 9 payments
  10. Allergan Inc. $128 7 payments
  11. Other $937 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,083 203 payments
  2. Education $95 1 payment
Products named General payments · program years 2019–2025
  1. SKYRIZI $394 27 payments
  2. DUPIXENT Inflammation And Immunology $295 11 payments
  3. DUPIXENT Immunology $285 12 payments
  4. RINVOQ $222 12 payments
  5. TREMFYA $191 6 payments
  6. DUPIXENT Immunology And Inflammation $160 6 payments
  7. EUCRISA $150 8 payments
  8. Zoryve $148 7 payments
  9. Seysara $132 7 payments
  10. DORYX $132 13 payments
  11. Other $2,294 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

204 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record